Antibodies

Eptinezumab initiated during a migraine prolongs time to subsequent attacks 4:37
Eptinezumab initiated during a migraine prolongs time to subsequent attacks
Roger Cady • 15 Jun 2021
Patient-identified most bothersome symptom as a novel outcome measure in migraine prevention trials 2:41
Patient-identified most bothersome symptom as a novel outcome measure in migraine prevention trials
Roger Cady • 15 Jun 2021
How does eptinezumab differ from other migraine treatments? 2:27
How does eptinezumab differ from other migraine treatments?
Roger Cady • 15 Jun 2021
RELIEF trial results: eptinezumab demonstrates efficacy when administered during a migraine attack 4:47
RELIEF trial results: eptinezumab demonstrates efficacy when administered during a migraine attack
Roger Cady • 15 Jun 2021
Exciting developments in the neuromuscular field 1:52
Exciting developments in the neuromuscular field
Gabriele Siciliano • 15 Jun 2021
Work productivity improves in patients with RRMS treated with ocrelizumab 4:55
Work productivity improves in patients with RRMS treated with ocrelizumab
Giancarlo Comi • 21 Jun 2021
Why are B-cells such a valuable target in MS? 3:09
Why are B-cells such a valuable target in MS?
Giancarlo Comi • 21 Jun 2021
Real-world comparison of natalizumab exit strategies in patients with RRMS 9:25
Real-world comparison of natalizumab exit strategies in patients with RRMS
Aurora Zanghì • 22 Jun 2021
Apitegromab for the treatment of SMA 2:49
Apitegromab for the treatment of SMA
Gabriele Siciliano • 15 Jun 2021
Next steps in MS treatment: optimizing what we have 3:36
Next steps in MS treatment: optimizing what we have
Giancarlo Comi • 21 Jun 2021
Benefits of SC natalizumab in MS 2:43
Benefits of SC natalizumab in MS
Bart Van Wijmeersch • 23 Jun 2021
Enhancing convenience and flexibility with SC natalizumab for MS 2:19
Enhancing convenience and flexibility with SC natalizumab for MS
Bart Van Wijmeersch • 23 Jun 2021
Plasma exchange in the treatment landscape of AD 1:46
Plasma exchange in the treatment landscape of AD
Javier Olazarán • 18 Jun 2021
Imaging biomarkers in migraine 2:52
Imaging biomarkers in migraine
Roberta Messina • 17 Jun 2021
Migraine symptom resolution occurs within an hour with eptinezumab administered during an attack 6:17
Migraine symptom resolution occurs within an hour with eptinezumab administered during an attack
Jessica Ailani • 21 Jun 2021
Total pain burden reduced by galcanezumab in treatment-resistant migraine 6:19
Total pain burden reduced by galcanezumab in treatment-resistant migraine
Jessica Ailani • 21 Jun 2021
The content of VJNeurology is intended for healthcare professionals